Roche Competitors and Similar CompaniesClear all
Agilent Technologies's competitors and similar companies include Thermo Fisher Scientific, Leica Biosystems Nussloch, Dexcom, GSK, Amgen, Johnson & Johnson, Bayer, Abbott, Danaher, Pfizer and Becton, Dickinson and Company.
 Agilent Technologies Agilent Technologies is a company that designs and manufactures laboratory instruments. |  Thermo Fisher Scientific Thermo Fisher Scientific is a company specializing in laboratory equipment, analytical instruments, reagents, consumables, and related technologies for scientific research and applied testing. |  Leica Biosystems Nussloch Leica Biosystems Nussloch is a medical device company that develops cancer diagnostic products. |  Dexcom Dexcom is a company that specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. |  Abbott Abbott Laboratories is a company that specializes in the discovery, development, manufacture, and sale of healthcare products. |  Danaher Danaher (formerly known as Diversified Mortgage Investors) is a life sciences and diagnostics company that manages and operates its group companies. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Becton, Dickinson and Company Becton, Dickinson and Company (BD) is a company that develops, manufactures, and sells medical supplies, laboratory equipment, and diagnostic products. | ||
Founding Date | Founding Date 1999 | Founding Date 1956 | Founding Date 1989 | Founding Date 1999 | Founding Date 2000 | Founding Date 1980 | Founding Date 1886 | Founding Date 1863 | Founding Date 1888 | Founding Date 1984 | Founding Date 1849 | Founding Date 1897 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Santa Clara, US HQ Victoria, AU Wien, AT Zaventem, BE Barueri, BR Mississauga, CA Beijing, CN see more | Locations Waltham, US HQ Buenos Aires, AR Buenos Aires, AR Buenos Aires, AR Adelaide Airport, AU Brendale, AU Canberra, AU see more | Locations Nußloch, DE HQ Mumbai, IN Buffalo Grove, US Deer Park, US | Locations San Diego, US HQ Brunn Am Gebirge, AT Burnaby, CA Mainz, DE Horw, CH Camberley, GB | Locations London, GB HQ Boumerdes, DZ Buenos Aires, AR Abbotsford, AU Wien, AT Wavre, BE Rio De Janeiro, BR see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Vienna, AT Minsk, BY Beerse, BE Sofia, BG see more | Locations Abbott Park, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Washington, US HQ Mount Waverley, AU Vienna, AT Ghent, BE Sao Paolo, BR Vancouver, CA Shanghai, CN see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations Franklin Lakes, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Wien, AT Aalst, BE Olen, BE see more | |
Employees | Employees 18,0001% decrease | Employees 125,000 | Employees 38918% increase | Employees 9,50027% increase | Employees 68,629 | Employees 25,200 | Employees 138,1005% increase | Employees 88,5021% decrease | Employees 114,000 | Employees 60,0002% decrease | Employees 81,0008% decrease | Employees 72,0003% increase |
Valuation ($) | Valuation ($) 37.7 b | Valuation ($) 209.2 b | Valuation ($) N/A | Valuation ($) 28.2 b | Valuation ($) 862.5 m | Valuation ($) 170.4 b | Valuation ($) 396.3 b | Valuation ($) 27.1 b | Valuation ($) 196.1 b | Valuation ($) 175.3 b | Valuation ($) 163.9 b | Valuation ($) 68.7 b |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) $6.9b (FY, 2025) | Revenue (est.) $44.6b (FY, 2025) | Revenue (est.) $254.8m (FY, 2022) | Revenue (est.) $4.7b (FY, 2025) | Revenue (est.) £32.7b (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $94.2b (FY, 2025) | Revenue (est.) €45.6b (FY, 2025) | Revenue (est.) $44.3b (FY, 2025) | Revenue (est.) $24.6b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) $21.8b (FY, 2025) |
Cost of goods | Cost of goods $3.3b (FY, 2025) | Cost of goods $26.3b (FY, 2025) | Cost of goods $154.7m (FY, 2022) | Cost of goods $1.9b (FY, 2025) | Cost of goods £5.6b (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods $30.3b (FY, 2025) | Cost of goods €14b (FY, 2025) | Cost of goods $19.3b (FY, 2025) | Cost of goods $10b (FY, 2025) | Cost of goods $16.1b (FY, 2025) | Cost of goods $11.9b (FY, 2025) |
Gross profit | Gross profit $3.6b (FY, 2025) | Gross profit $18.2b (FY, 2025) | Gross profit $100.1m (FY, 2022) | Gross profit $2.8b (FY, 2025) | Gross profit £28.5b (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit $63.9b (FY, 2025) | Gross profit €32.5b (FY, 2025) | Gross profit $25b (FY, 2025) | Gross profit $14.5b (FY, 2025) | Gross profit $46.5b (FY, 2025) | Gross profit $9.9b (FY, 2025) |
Net income | Net income $1.3b (FY, 2025) | Net income $6.7b (FY, 2025) | Net income $32.6m (FY, 2022) | Net income $836.3m (FY, 2025) | Net income £6.3b (FY, 2025) | Net income $7.7b (FY, 2025) | Net income $26.8b (FY, 2025) | Net income (€3.6b) (FY, 2025) | Net income $6.5b (FY, 2025) | Net income $3.6b (FY, 2025) | Net income $7.8b (FY, 2025) | Net income $1.7b (FY, 2025) |
Operating ⚠ | ||||||||||||
Business Segments | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments N/A | Business Segments 4 (FY, 2023) | Business Segments N/A | Business Segments 3 (FY, 2024) |
Countries | Countries N/A | Countries 70 (FY, 2023) | Countries 35 (Feb, 2024) | Countries N/A | Countries 92 (FY, 2021) | Countries 100 (FY, 2020) | Countries N/A | Countries 83 (FY, 2021) | Countries N/A | Countries 50 (FY, 2023) | Countries 200 (FY, 2024) | Countries N/A |
Facilities | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 180 (FY, 2020) | Facilities N/A | Facilities N/A | Facilities N/A | Facilities 184 (FY, 2023) | Facilities N/A | Facilities N/A |
Facility Space Leased, sq. ft. | Facility Space Leased, sq. ft. 1.5 m (FY, 2024) | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. N/A | Facility Space Leased, sq. ft. 8 m (FY, 2024) |
Facility Space Owned, sq. ft. | Facility Space Owned, sq. ft. 5.3 m (FY, 2024) | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. N/A | Facility Space Owned, sq. ft. 18.5 m (FY, 2024) |
Facility Space, sq. ft. | Facility Space, sq. ft. 6.8 m (FY, 2024) | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. 44 m (FY, 2023) | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A | Facility Space, sq. ft. N/A |
Manufacturing Sites | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 6 (Feb, 2024) | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites N/A | Manufacturing Sites 37 (FY, 2024) | Manufacturing Sites N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products N/A |
Remaining Performance Obligations | Remaining Performance Obligations N/A | Remaining Performance Obligations $25.3b (Q3, 2024) | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A | Remaining Performance Obligations $4.5b (Q2, 2024) | Remaining Performance Obligations N/A | Remaining Performance Obligations N/A |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A | Suppliers N/A | Suppliers 93.8 k (FY, 2021) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A |
Trademarks | Trademarks N/A | Trademarks N/A | Trademarks 170 (Feb, 2024) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks 1.5 k (FY, 2021) | Trademarks N/A | Trademarks N/A | Trademarks N/A | Trademarks N/A |
Trademarks Pending | Trademarks Pending N/A | Trademarks Pending N/A | Trademarks Pending 3 (Feb, 2024) | Trademarks Pending N/A | Trademarks Pending N/A | Trademarks Pending N/A | Trademarks Pending N/A | Trademarks Pending 74 (FY, 2021) | Trademarks Pending N/A | Trademarks Pending N/A | Trademarks Pending N/A | Trademarks Pending N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 500m | Total funding raised N/A | Total funding raised $ 2.7b | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 3.5b | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Thermo Fisher Scientific
HQ
Waltham, US
Employees
125,000
Thermo Fisher Scientific is a company specializing in laboratory equipment, analytical instruments, reagents, consumables, and related technologies for scientific research and applied testing.
View companyLeica Biosystems Nussloch
HQ
Nußloch, DE
Leica Biosystems Nussloch is a medical device company that develops cancer diagnostic products.
View companyDexcom
HQ
San Diego, US
Employees
9,500↑ 27% increase
Dexcom is a company that specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes.
View companyGSK
HQ
London, GB
Employees
68,629
GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products.
View company